# OnCo record idarubicin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/idarubicin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "idarubicin" ;
  schema:name "Idarubicin"@en ;
  schema:description "Idarubicin is an anthracycline chemotherapy approved in 1990 for adult acute myeloid leukaemia, given with cytarabine in 3+7 induction and FLAG-Ida salvage and in acute promyelocytic leukaemia protocols. Randomised trials showed more complete remissions than with daunorubicin, which is why centres prefer it; heart damage, marrow suppression and extravasation injury are the class risks."@en ;
  schema:url <https://onco.cc/drugs/idarubicin/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Idarubicin> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=idarubicin>, <https://www.cancer.gov/about-cancer/treatment/drugs/idarubicinhydrochloride> ;
  onco:status "approved" ;
  onco:tag "nci-list", "generic" ;
  onco:modality "Anthracycline (topoisomerase II inhibitor)" ;
  schema:alternateName "Idamycin PFS" ;
  onco:approval "US 1990: Adult acute myeloid leukaemia, as a component of combination induction chemotherapy" ;
  onco:related <https://onco.cc/drugs/daunorubicin/>, <https://onco.cc/drugs/cytarabine/> ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:trials <https://onco.cc/trials/nct03591510/> .